1-4 of 4
Chengfei Pu
Close
Sort by
Journal Articles

Dose Escalation Study of GCC19CART CoupledCAR ® Technology for Patients with Relapsed or Refractory Colorectal Cancer

Naifei Chen, Chengfei Pu, Lingling Zhao, Chang Wang, Ruihong Zhu, Tingting Liang, Xi Huang, Haiyang Tang, Yizhuo Wang, Beibei Jia, Dongqi Chen, Eugene Kennedy, Zhao Wu, Lei Xiao, Jiuwei Cui
Journal: Blood
Blood (2021) 138 (Supplement 1): 4841.
https://doi.org/10.1182/blood-2021-153429
Published: 2021
Journal Articles

Novel CoupledCAR TM Technology for Treating Colorectal Cancer

Lei Xiao, PhD, Song Li, Chengfei Pu, Zhiyuan Cao, Xinyi Yang, Ning Li, Youli Luo, Haiyan Zhao, Hang Yang, Xi Huang, Xiaogang Shen, Xiuwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu
Journal: Blood
Blood (2020) 136 (Supplement 1): 54.
https://doi.org/10.1182/blood-2020-140653
Published: 2020
Journal Articles

CoupledCAR TM Technology for Treating Thyroid Cancer

Xingchen Liu, Lei Xiao, PhD, Keshu Zhou, Yu Liu, Yong Huang, Chengfei Pu, Zhiyuan Cao, Ruihong Zhu, Haiyang Tang, Zhipeng Huang, Hang Yang, Xi Huang, Yongping Song, Renbin Liu, Zhao Wu
Journal: Blood
Blood (2020) 136 (Supplement 1): 46.
https://doi.org/10.1182/blood-2020-138668
Published: 2020
Journal Articles

CD19 CAR-T Cells Administered after High-Dose Cyclophosphamide Chemotherapy Induce Rapid Remissions of Chemotherapy-Refractory Acute B-Cell Leukemia with High Tumor Burden

Yongxia Hu, Lei Xiao, Zhao Wu, Yi Luo, Chengfei Pu, Guoqing Wei, He Huang, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4909.
https://doi.org/10.1182/blood.V126.23.4909.4909
Published: 2015